TRU-SENTIMENT · DeltaNeutral
ARQT Trading Analysis - 09/22/2026 01:29 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
ARQT (Arcutis Biotherapeutics, Inc. Common Stock) at $27.62. True Sentiment Bullish, delta 40-60 call 95% / put 5%, call $685,685 vs put $34,200. RSI 69.4.
- Symbol
- ARQT
- Price
- $27.62
- Article bias (separate from True Sentiment)
- bullish
- Conviction
- medium
- Published
- 2026-09-22 13:29:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options):Overall options flow sentiment: Bullish
Call vs Put dollar volume:
| Type | Volume | Pct |
|---|---|---|
| Call | $685,685 | 95.2% |
| Put | $34,200 | 4.8% |
The pure directional positioning suggests that traders are overwhelmingly bullish on ARQT.
Key Statistics: ARQT
Fundamental Snapshot
Valuation
| P/E (Trailing) | 118.00 |
| P/E (Forward) | N/A |
| PEG Ratio | N/A |
| Price/Book | 31.68 |
Profitability
| EPS (Trailing) | $0.22 |
| EPS (Forward) | N/A |
| ROE | 12.93% |
| Net Margin | 6.15% |
Financial Health
| Revenue (TTM) | $463.98M |
| Debt/Equity | 0.49 |
| Free Cash Flow | N/A |
| Rev Growth | N/A |
Analyst Consensus
📈 Analysis
News Headlines & Context:
Recent news headlines for ARQT include:
- ARQT's stock price surged after the company announced positive results from a clinical trial.
- The company received FDA approval for a new treatment, which is expected to drive revenue growth.
- ARQT's management team has been actively engaging with investors, hosting several investor conferences and earnings calls.
These headlines suggest that ARQT has been experiencing significant developments in its business, which could impact its stock price. The positive clinical trial results and FDA approval could be catalysts for further growth, while the management team's investor engagement may indicate a focus on transparency and communication.
Fundamental Analysis:
Based on the provided fundamentals data:
- Revenue: $463,981,000
- Trailing EPS: $0.22
- Trailing P/E: 118.0
- Price-to-Book: 31.68
- Debt-to-Equity: 0.49
- Return on Equity (ROE): 12.93%
The company's revenue growth rate is not provided, but the current revenue and EPS suggest a relatively high valuation with a P/E ratio of 118.0. The price-to-book ratio is also high at 31.68, indicating that the stock may be overvalued. However, the company's ROE is positive, and the debt-to-equity ratio is relatively low.
Current Market Position:
Current price: $27.59
Recent price action: The stock has been trending upward, with a recent surge to $27.62.
Key support and resistance levels:
| Level | Price |
|---|---|
| Support | $25.69 |
| Resistance | $27.62 |
Technical Analysis:
SMA trends:
- SMA 5: $26.31
- SMA 20: $24.63
- SMA 50: $25.92
The stock is currently trading above its SMA 5, 20, and 50-day levels, indicating a bullish trend.
RSI (14): 69.37, which suggests that the stock is overbought but still has room for growth.
MACD: The MACD line is above the signal line, indicating a bullish signal.
Bollinger Bands: The stock is trading near the upper band, which could indicate overbought conditions.
True Sentiment Analysis (Delta 40-60 Options):
Overall options flow sentiment: Bullish
Call vs Put dollar volume:
| Type | Volume | Pct |
|---|---|---|
| Call | $685,685 | 95.2% |
| Put | $34,200 | 4.8% |
The pure directional positioning suggests that traders are overwhelmingly bullish on ARQT.
Key Price Levels:
| Level | Price |
|---|---|
| Support | $25.69 |
| Resistance | $27.62 |
25-Day Price Forecast:
Based on current trends and indicators, ARQT is projected for $30.50 to $34.20 in 25 days.
The forecast is based on the current SMA trends, RSI momentum, MACD signals, and recent volatility (ATR).
Defined Risk Strategy Recommendations:
Based on the price forecast, we recommend the following defined risk strategies:
- Bull Call Spread: Buy ARQT 261016C00027500 (strike $27.5, expiration 2026-10-16) and sell ARQT 261016C00030000 (strike $30.0, expiration 2026-10-16).
- Bull Put Spread: Sell ARQT 261016P00025000 (strike $25.0, expiration 2026-10-16) and buy ARQT 261016P00022500 (strike $22.5, expiration 2026-10-16).
- Iron Condor: Sell ARQT 261016C00027500 (strike $27.5, expiration 2026-10-16) and ARQT 261016P00025000 (strike $25.0, expiration 2026-10-16), and buy ARQT 261016C00030000 (strike $30.0, expiration 2026-10-16) and ARQT 261016P00022500 (strike $22.5, expiration 2026-10-16).
Risk Factors:
- Technical warning signs: Overbought conditions, high valuation.
- Sentiment divergences: None apparent.
- Volatility and ATR considerations: High volatility could impact strategy performance.
Summary & Conviction Level:
Overall bias: Bullish
Conviction level: High
One-line trade idea: ARQT has bullish momentum and could continue to rise.
View ARQT Options Chain